|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1100 NEW YORK AVENUE, NW, #440 E |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 69674-12
|
||||||||
|
6. House ID# 357890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Leslie Ritter |
Date | 10/16/2019 12:23:29 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2740- Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020
oIncluded department of Defense Appropriations Act, 2019, support $16 million for the MSRP. Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act, 2019, support $41.6 billion for the National Institutes of Health (NIH); $8.445 billion for the Centers for Disease Control and Prevention inclusive of $5 million to establish the National Neurological Conditions Surveillance System; $10 million for the Lifespan Respite Care Program; $150 million for the Patient-Centered Outcomes Research Institute; $454 million for the Agency for Healthcare Research and Quality; and robust funding for the SSAs administrative budget.
H.R. 3055- Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020
oSupporting $3.3 billion for the Food and Drug Administration.
Supporting same funding levels in Senate for these programs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Grant |
Couch |
|
|
|
Leslie |
Ritter |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
- H.R. 965/ S. 340, Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act), support passage.
- H.R. 985, Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act), support passage.
-H.R. 2035/S. 995, Lifespan Respite Care Reauthorization Act, support reauthorization
- H.R. 3208/ S.1755 - Real Emergency Access for Aging and Disability Inclusion for Disasters Act, support passage
- H.R. 3215/ S. 1754 - Disaster Relief Medicaid Act, support passage
- S.2400/ H.R. 4322 - Expanding Cannabis Research and Information Act, support passage
- H.R. 3439 - Reauthorization of the Patient Centered Outcomes Research Institute, support reauthorization.
-H.R. 2781 - Empower for Health Act of 2019, support passage
-H.R. 2035, Lifespan Respite Care Reauthorization Act of 2019, support passage
-H.R. 2296/S.1391 - FAIR Drug Pricing Act of 2019, support passage
- H.R. 3630 - No Surprises Act, support passage
-H.R. 1010, To provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect, support passage.
-H.R. 986, The Protecting Americans with Preexisting Conditions Act of 2019, support passage.
-H.R.1386, Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act of 2019, support passage.
-H.R. 2293, the Protecting Access to Wheelchairs Act, support passage.
-H.R. 2408, the Ensuring Access to Quality Complex Rehabilitation Technology Act, support passage.
-H.R 3 - Lower Drug Costs Now Act of 2019, support passage
-S. 1935, Family Coverage Act, support passage.
-S.1556, No Junk Plans Act, support passage.
-S. 1223, the Protecting Beneficiary Access to Complex Rehab Technology Act, support passage
- S.475, Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2019 (RX Cap Act), support passage
- S. 637, Combatting Unreasonable Rises and Excessively High Drug Prices Act (CURE High Drug Prices Act), support passage
- S.366, Forcing Limits on Abusive and Tumultuous Prices (FLAT Prices) Act, support passage
-S. 63, Preserve Access to Affordable Generics and Biosimilars Act, support passage
-S. 659, Biologic Patent Transparency Act, support passage
-S.1895 - Lower Health Care Costs Act, support passage
- S. 1280/HR 2477 - Beneficiary Enrollment Notification and Eligibility Simplification (BENES) Act, support passage
- S. 691 - Medicare Extra Rx Help Act- support passage
- S. 2543 - Prescription Drug Price Reduction Act of 2019 - support passage
- Menendez - Lankford- Cardin-Daines Amendment 1
Incentivizing Generic and Biosimilar Use in Medicare Part D - support adoption
-Menendez -Lankford - Cardin --Daines Amendment 2
Incentivizing Generic Use in Medicare Part D - support adoption
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Calder |
|
|
|
Leslie |
Ritter |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
N/A
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kimberly |
Calder |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
N/A
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Grant |
Couch |
|
|
|
Leslie |
Ritter |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
N/A
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
N/A
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leslie |
Ritter |
|
|
|
Grant |
Couch |
|
|
|
Jacob |
Goodman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
No foreign interests.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |